Last updated: 2026-09-04 16:06:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Century Therapeutics, Inc. (IPSC) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2.12, with a market capitalisation of $382.07M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.44 to $3.04. This page covers its latest market performance, valuation, price trends and company information.
$382.07M | |
$2.06 | |
$32.90 | |
$0.34 | |
$2.09 | |
34.72K | |
-- | |
-- | |
$3.04 | |
$0.44 | |
-- | |
-- |
Century Therapeutics, Inc. (IPSC) is currently trading at $2.12 as of 2026-09-04 16:05:00, up 1.20% ($0.03) from the previous close of $2.09
During today's regular trading session, IPSC has traded between $0.34 and $32.90, with a trading volume of 34.72K shares. The current price is near the lower end of today's range.
Over the past seven days, Century Therapeutics, Inc. (IPSC) moved from $2.00 to $2.12, representing a gain of 5.75% ($0.12).
The stock traded between $2.06 and $2.12 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 385.32 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 64.5%
IPSC is currently trading at $2.12, placing it 64.5% of the way from its 52-week low of $0.44 to its 52-week high of $3.04. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 78 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Century Therapeutics, Inc. (IPSC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.